vs

Side-by-side financial comparison of MEDIFAST INC (MED) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.

TRICO BANCSHARES is the larger business by last-quarter revenue ($109.4M vs $75.1M, roughly 1.5× MEDIFAST INC). On growth, TRICO BANCSHARES posted the faster year-over-year revenue change (9.0% vs -36.9%). TRICO BANCSHARES produced more free cash flow last quarter ($127.9M vs $-6.6M). Over the past eight quarters, TRICO BANCSHARES 's revenue compounded faster (5.4% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.

MED vs TCBK — Head-to-Head

Bigger by revenue
TCBK
TCBK
1.5× larger
TCBK
$109.4M
$75.1M
MED
Growing faster (revenue YoY)
TCBK
TCBK
+45.9% gap
TCBK
9.0%
-36.9%
MED
More free cash flow
TCBK
TCBK
$134.6M more FCF
TCBK
$127.9M
$-6.6M
MED
Faster 2-yr revenue CAGR
TCBK
TCBK
Annualised
TCBK
5.4%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
TCBK
TCBK
Revenue
$75.1M
$109.4M
Net Profit
$33.6M
Gross Margin
69.4%
Operating Margin
-10.4%
42.6%
Net Margin
251.6%
Revenue YoY
-36.9%
9.0%
Net Profit YoY
15.8%
EPS (diluted)
$-1.64
$1.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
TCBK
TCBK
Q4 25
$75.1M
$109.4M
Q3 25
$89.4M
$107.6M
Q2 25
$105.6M
$103.6M
Q1 25
$115.7M
$98.6M
Q4 24
$119.0M
$100.4M
Q3 24
$140.2M
$99.1M
Q2 24
$168.6M
$97.9M
Q1 24
$174.7M
$98.5M
Net Profit
MED
MED
TCBK
TCBK
Q4 25
$33.6M
Q3 25
$-2.3M
$34.0M
Q2 25
$2.5M
$27.5M
Q1 25
$-772.0K
$26.4M
Q4 24
$29.0M
Q3 24
$1.1M
$29.1M
Q2 24
$-8.2M
$29.0M
Q1 24
$8.3M
$27.7M
Gross Margin
MED
MED
TCBK
TCBK
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
TCBK
TCBK
Q4 25
-10.4%
42.6%
Q3 25
-4.6%
43.2%
Q2 25
-1.0%
36.5%
Q1 25
-1.1%
35.8%
Q4 24
0.6%
38.7%
Q3 24
1.5%
39.8%
Q2 24
-4.7%
40.0%
Q1 24
4.5%
38.3%
Net Margin
MED
MED
TCBK
TCBK
Q4 25
251.6%
Q3 25
-2.5%
31.6%
Q2 25
2.3%
26.6%
Q1 25
-0.7%
26.7%
Q4 24
221.4%
Q3 24
0.8%
29.3%
Q2 24
-4.8%
29.7%
Q1 24
4.8%
28.2%
EPS (diluted)
MED
MED
TCBK
TCBK
Q4 25
$-1.64
$1.02
Q3 25
$-0.21
$1.04
Q2 25
$0.22
$0.84
Q1 25
$-0.07
$0.80
Q4 24
$0.08
$0.88
Q3 24
$0.10
$0.88
Q2 24
$-0.75
$0.87
Q1 24
$0.76
$0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
TCBK
TCBK
Cash + ST InvestmentsLiquidity on hand
$167.3M
$157.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$1.3B
Total Assets
$248.0M
$9.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
TCBK
TCBK
Q4 25
$167.3M
$157.0M
Q3 25
$173.5M
$298.8M
Q2 25
$162.7M
$314.3M
Q1 25
$164.6M
$308.3M
Q4 24
$162.3M
$145.0M
Q3 24
$170.0M
$320.1M
Q2 24
$163.5M
$206.6M
Q1 24
$156.4M
$82.8M
Stockholders' Equity
MED
MED
TCBK
TCBK
Q4 25
$198.9M
$1.3B
Q3 25
$214.7M
$1.3B
Q2 25
$216.0M
$1.3B
Q1 25
$211.0M
$1.3B
Q4 24
$210.1M
$1.2B
Q3 24
$207.3M
$1.2B
Q2 24
$205.3M
$1.2B
Q1 24
$211.0M
$1.2B
Total Assets
MED
MED
TCBK
TCBK
Q4 25
$248.0M
$9.8B
Q3 25
$268.2M
$9.9B
Q2 25
$269.3M
$9.9B
Q1 25
$280.0M
$9.8B
Q4 24
$284.2M
$9.7B
Q3 24
$291.2M
$9.8B
Q2 24
$293.5M
$9.7B
Q1 24
$302.8M
$9.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
TCBK
TCBK
Operating Cash FlowLast quarter
$-5.3M
$133.3M
Free Cash FlowOCF − Capex
$-6.6M
$127.9M
FCF MarginFCF / Revenue
-8.8%
116.9%
Capex IntensityCapex / Revenue
1.8%
4.9%
Cash ConversionOCF / Net Profit
3.96×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$222.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
TCBK
TCBK
Q4 25
$-5.3M
$133.3M
Q3 25
$12.1M
$45.1M
Q2 25
$-3.4M
$29.2M
Q1 25
$3.4M
$24.5M
Q4 24
$-4.9M
$109.7M
Q3 24
$9.1M
$28.6M
Q2 24
$13.1M
$31.8M
Q1 24
$7.3M
$25.1M
Free Cash Flow
MED
MED
TCBK
TCBK
Q4 25
$-6.6M
$127.9M
Q3 25
$10.8M
$43.2M
Q2 25
$-4.8M
$28.2M
Q1 25
$1.9M
$22.8M
Q4 24
$-7.2M
$105.2M
Q3 24
$7.7M
$27.3M
Q2 24
$11.1M
$30.8M
Q1 24
$5.4M
$24.1M
FCF Margin
MED
MED
TCBK
TCBK
Q4 25
-8.8%
116.9%
Q3 25
12.0%
40.2%
Q2 25
-4.5%
27.2%
Q1 25
1.6%
23.1%
Q4 24
-6.1%
104.8%
Q3 24
5.5%
27.6%
Q2 24
6.6%
31.5%
Q1 24
3.1%
24.4%
Capex Intensity
MED
MED
TCBK
TCBK
Q4 25
1.8%
4.9%
Q3 25
1.5%
1.7%
Q2 25
1.3%
1.0%
Q1 25
1.3%
1.7%
Q4 24
1.9%
4.5%
Q3 24
1.0%
1.3%
Q2 24
1.1%
1.0%
Q1 24
1.1%
1.0%
Cash Conversion
MED
MED
TCBK
TCBK
Q4 25
3.96×
Q3 25
1.33×
Q2 25
-1.36×
1.06×
Q1 25
0.93×
Q4 24
3.78×
Q3 24
8.04×
0.98×
Q2 24
1.10×
Q1 24
0.88×
0.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons